These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16542205)

  • 1. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
    Bernsdorf A; Giessmann T; Modess C; Wegner D; Igelbrink S; Hecker U; Haenisch S; Cascorbi I; Terhaag B; Siegmund W
    Br J Clin Pharmacol; 2006 Apr; 61(4):440-50. PubMed ID: 16542205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.
    Haenisch S; May K; Wegner D; Caliebe A; Cascorbi I; Siegmund W
    Pharmacogenet Genomics; 2008 Apr; 18(4):357-65. PubMed ID: 18334920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
    Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
    Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
    Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans.
    Giessmann T; May K; Modess C; Wegner D; Hecker U; Zschiesche M; Dazert P; Grube M; Schroeder E; Warzok R; Cascorbi I; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2004 Sep; 76(3):192-200. PubMed ID: 15371980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.
    Siegmund W; Ludwig K; Giessmann T; Dazert P; Schroeder E; Sperker B; Warzok R; Kroemer HK; Cascorbi I
    Clin Pharmacol Ther; 2002 Nov; 72(5):572-83. PubMed ID: 12426521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.
    Oswald S; Haenisch S; Fricke C; Sudhop T; Remmler C; Giessmann T; Jedlitschky G; Adam U; Dazert E; Warzok R; Wacke W; Cascorbi I; Kroemer HK; Weitschies W; von Bergmann K; Siegmund W
    Clin Pharmacol Ther; 2006 Mar; 79(3):206-17. PubMed ID: 16513445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition.
    Siegmund W; Altmannsberger S; Paneitz A; Hecker U; Zschiesche M; Franke G; Meng W; Warzok R; Schroeder E; Sperker B; Terhaag B; Cascorbi I; Kroemer HK
    Clin Pharmacol Ther; 2002 Sep; 72(3):256-64. PubMed ID: 12235446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
    Giessmann T; Modess C; Hecker U; Zschiesche M; Dazert P; Kunert-Keil C; Warzok R; Engel G; Weitschies W; Cascorbi I; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2004 Mar; 75(3):213-22. PubMed ID: 15001973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
    Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
    Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins.
    Oswald S; Giessmann T; Luetjohann D; Wegner D; Rosskopf D; Weitschies W; Siegmund W
    Clin Pharmacol Ther; 2006 Nov; 80(5):477-85. PubMed ID: 17112804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
    Niemi M; Arnold KA; Backman JT; Pasanen MK; Gödtel-Armbrust U; Wojnowski L; Zanger UM; Neuvonen PJ; Eichelbaum M; Kivistö KT; Lang T
    Pharmacogenet Genomics; 2006 Nov; 16(11):801-8. PubMed ID: 17047488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.
    Haenisch S; Zimmermann U; Dazert E; Wruck CJ; Dazert P; Siegmund W; Kroemer HK; Warzok RW; Cascorbi I
    Pharmacogenomics J; 2007 Feb; 7(1):56-65. PubMed ID: 16788565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
    Hedman M; Antikainen M; Holmberg C; Neuvonen M; Eichelbaum M; Kivistö KT; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2006 Jun; 61(6):706-15. PubMed ID: 16722833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the multidrug transporter proteins ABCB1 and ABCC2 in the diaplacental transport of talinolol in the term human placenta.
    May K; Minarikova V; Linnemann K; Zygmunt M; Kroemer HK; Fusch C; Siegmund W
    Drug Metab Dispos; 2008 Apr; 36(4):740-4. PubMed ID: 18195111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism.
    He X; Mo L; Li ZY; Tan ZR; Chen Y; Ouyang DS
    Xenobiotica; 2012 Dec; 42(12):1248-54. PubMed ID: 22725663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
    Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
    Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
    Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
    Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters.
    Matthaei J; Tzvetkov MV; Gal V; Sachse-Seeboth C; Sehrt D; Hjelmborg JB; Hofmann U; Schwab M; Kerb R; Brockmöller J
    Genome Med; 2016 Nov; 8(1):119. PubMed ID: 27825374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grapefruit juice ingestion significantly reduces talinolol bioavailability.
    Schwarz UI; Seemann D; Oertel R; Miehlke S; Kuhlisch E; Fromm MF; Kim RB; Bailey DG; Kirch W
    Clin Pharmacol Ther; 2005 Apr; 77(4):291-301. PubMed ID: 15903127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.